Oncolytics Biotech Company Profile (NASDAQ:ONCY)

About Oncolytics Biotech (NASDAQ:ONCY)

Oncolytics Biotech logoOncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.

Industry, Sector and Symbol: Average Prices:
  • 50 Day Moving Avg: $0.34
  • 200 Day Moving Avg: $0.50
  • 52 Week Range: $0.24 - $1.40
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.50
  • P/E Growth: 0.00
  • Return on Equity: -161.95%
  • Return on Assets: -123.71%
  • Average Volume: 279,022 shs.

Frequently Asked Questions for Oncolytics Biotech (NASDAQ:ONCY)

What is Oncolytics Biotech's stock symbol?

Oncolytics Biotech trades on the NASDAQ under the ticker symbol "ONCY."

How were Oncolytics Biotech's earnings last quarter?

Oncolytics Biotech, Inc. (NASDAQ:ONCY) released its earnings results on Thursday, August, 6th. The company reported ($0.03) earnings per share for the quarter, topping analysts' consensus estimates of ($0.04) by $0.01. View Oncolytics Biotech's Earnings History.

Who are some of Oncolytics Biotech's key competitors?

Who are Oncolytics Biotech's key executives?

Oncolytics Biotech's management team includes the folowing people:

  • Wayne F. Pisano, Chairman of the Board
  • Matthew C. Coffey Ph.D., President, Chief Executive Officer, Chief Operating Officer, Director
  • Kirk J. Look, Chief Financial Officer
  • George M. Gill M.D., Senior Vice President - Regulatory Affairs & Chief Safety Officer
  • Mary Ann Dillahunty J.D., Vice President - Intellectual Property
  • Andres A. Gutierrez M.D., PhD., Chief Medical Officer
  • Alan J. Tuchman M.D., Chief Neuro Oncology Research Officer
  • Angela Frances Holtham, Director
  • Edwin Levy Ph.D., Director
  • J. Mark Lievonen, Director

How do I buy Oncolytics Biotech stock?

Shares of Oncolytics Biotech can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Oncolytics Biotech's stock price today?

One share of Oncolytics Biotech stock can currently be purchased for approximately $0.33.

MarketBeat Community Rating for Oncolytics Biotech (NASDAQ ONCY)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  73 (Vote Outperform)
Underperform Votes:  49 (Vote Underperform)
Total Votes:  122
MarketBeat's community ratings are surveys of what our community members think about Oncolytics Biotech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Oncolytics Biotech (NASDAQ:ONCY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: N/A

Analysts' Ratings History for Oncolytics Biotech (NASDAQ:ONCY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/3/2016Royal Bank Of CanadaReiterated RatingOutperformN/AView Rating Details
(Data available from 9/26/2015 forward)


Earnings History for Oncolytics Biotech (NASDAQ:ONCY)
Earnings by Quarter for Oncolytics Biotech (NASDAQ:ONCY)
Earnings History by Quarter for Oncolytics Biotech (NASDAQ ONCY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2015Q215($0.04)($0.03)ViewN/AView Earnings Details
5/7/2015($0.06)($0.03)ViewN/AView Earnings Details
3/16/2015($0.06)($0.04)ViewN/AView Earnings Details
11/6/2014Q314($0.06)($0.05)ViewN/AView Earnings Details
8/7/2014Q214($0.07)($0.05)ViewN/AView Earnings Details
5/8/2014Q114($0.07)($0.06)ViewN/AView Earnings Details
3/13/2014Q413($0.09)($0.28)ViewN/AView Earnings Details
8/1/2013Q213($0.13)($0.06)ViewN/AView Earnings Details
5/9/2013Q113($0.09)($0.08)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Oncolytics Biotech (NASDAQ:ONCY)
Current Year EPS Consensus Estimate: $-0.18 EPS
Next Year EPS Consensus Estimate: $-0.06 EPS


Dividend History for Oncolytics Biotech (NASDAQ:ONCY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Oncolytics Biotech (NASDAQ:ONCY)
No insider trades for this company have been tracked by MarketBeat.com


Headline Trends for Oncolytics Biotech (NASDAQ:ONCY)
Latest Headlines for Oncolytics Biotech (NASDAQ:ONCY)



Oncolytics Biotech (ONCY) Chart for Tuesday, September, 26, 2017

This page was last updated on 9/26/2017 by MarketBeat.com Staff